The Polyomavirus Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Polyomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polyomavirus Infections. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polyomavirus Infections and features dormant and discontinued products.

GlobalData tracks 32 drugs in development for Polyomavirus Infections by 30 companies/universities/institutes. The top development phase for Polyomavirus Infections is preclinical with ten drugs in that stage. The Polyomavirus Infections pipeline has 24 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Polyomavirus Infections pipeline products market are: Biological E, Palisades Therapeutics and Vera Therapeutics.

The key targets in the Polyomavirus Infections pipeline products market include Major Capsid Protein VP1 (JC Polyomavirus Major Structural Protein VP1), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Tyrosine Protein Kinase ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1 or Abelson Tyrosine Protein Kinase 1 or Proto Oncogene c Abl or p150 or ABL1 or EC 2.7.10.2).

The key mechanisms of action in the Polyomavirus Infections pipeline product include Major Capsid Protein VP1 (JC Polyomavirus Major Structural Protein VP1) Inhibitor with two drugs in Discovery. The Polyomavirus Infections pipeline products include seven routes of administration with the top ROA being Intravenous and seven key molecule types in the Polyomavirus Infections pipeline products market including Cell Therapy, and Monoclonal Antibody.

Polyomavirus Infections overview

Polyomaviruses, a family of small DNA viruses, pose potential threats to human health. Among them, the BK virus (BKV) and JC virus (JCV) are known to infect humans, with implications for those with weakened immune systems. While these viruses can circulate without symptoms in the general population, immunocompromised individuals face complications. BKV may induce nephropathy or cystitis, particularly in organ transplant recipients. JCV, prevalent with many carrying antibodies, can lead to progressive multifocal leukoencephalopathy (PML), a severe brain disease, in those with compromised immune function.

For a complete picture of Polyomavirus Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.